Home › Funds › Avidity Partners Management LP › BBOT
Avidity Partners Management LP position in BBOT
BridgeBio Oncology Therapeutic Inc · Health Care
Avidity Partners Management LP reported holding 43,853 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$334K, representing 0.05% of its reported portfolio and ranking #43 among its reported holdings. Avidity Partners Management LP has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Avidity Partners Management LP's BBOT position evolved
Avidity Partners Management LP first disclosed a stake in BBOT in Q1 2026 at 43,853 shares (US$392K). Across 2 filings, Avidity Partners Management LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 43,853 shares valued at US$334K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 43.85K | $392.48K | New |
| Q2 2026 | 43.85K | $334.16K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- Alphabet Inc. 2.82M sh · $21.51M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Laurion Capital Management LP 2.00M sh · $15.26M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $7.76M · Q2 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
More on Avidity Partners Management LP
FAQ
How long has Avidity Partners Management LP held BBOT?
Avidity Partners Management LP has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Avidity Partners Management LP's current position in BBOT?
As of Q2 2026, Avidity Partners Management LP holds 43.85K shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $334.16K, representing 0.05% of its reported portfolio and ranking #43.
Has Avidity Partners Management LP been buying or selling BBOT?
In the latest 13F filing (Q2 2026), Avidity Partners Management LP held unchanged its position in BBOT.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.